Gimv: invests in Belgian biotech firm
(CercleFinance.com) - Belgian investment company Gimv is investing 6 million euros in Belgian biotech firm Camel-IDS, the group said in a statement on Thursday.
This transaction is part of the latest financing round obtained by Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals, whereby the company secured funding of 37 million euros.
This financing will enable Camel-IDS to run a phase Ib/II trial with its lead program targeting brain metastatic breast cancer, Gimv said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This transaction is part of the latest financing round obtained by Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals, whereby the company secured funding of 37 million euros.
This financing will enable Camel-IDS to run a phase Ib/II trial with its lead program targeting brain metastatic breast cancer, Gimv said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.